JP2013519363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519363A5 JP2013519363A5 JP2012552394A JP2012552394A JP2013519363A5 JP 2013519363 A5 JP2013519363 A5 JP 2013519363A5 JP 2012552394 A JP2012552394 A JP 2012552394A JP 2012552394 A JP2012552394 A JP 2012552394A JP 2013519363 A5 JP2013519363 A5 JP 2013519363A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- proinflammatory
- mature
- proinflammatory mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 dendritic cell Anatomy 0.000 claims 12
- 230000000770 proinflammatory effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30315310P | 2010-02-10 | 2010-02-10 | |
| SE1050133-6 | 2010-02-10 | ||
| US61/303,153 | 2010-02-10 | ||
| SE1050133 | 2010-02-10 | ||
| PCT/EP2011/051952 WO2011098516A1 (en) | 2010-02-10 | 2011-02-10 | Improved composition for inhibiting tumor cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519363A JP2013519363A (ja) | 2013-05-30 |
| JP2013519363A5 true JP2013519363A5 (enExample) | 2014-03-06 |
| JP5855018B2 JP5855018B2 (ja) | 2016-02-09 |
Family
ID=43903832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552394A Expired - Fee Related JP5855018B2 (ja) | 2010-02-10 | 2011-02-10 | 腫瘍細胞増殖を阻害するための改善された組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9034317B2 (enExample) |
| EP (1) | EP2534242B1 (enExample) |
| JP (1) | JP5855018B2 (enExample) |
| KR (1) | KR101770785B1 (enExample) |
| CN (1) | CN102782123B (enExample) |
| BR (1) | BR112012019267B1 (enExample) |
| DK (1) | DK2534242T3 (enExample) |
| ES (1) | ES2581277T3 (enExample) |
| HU (1) | HUE028352T2 (enExample) |
| PL (1) | PL2534242T3 (enExample) |
| RU (1) | RU2565542C2 (enExample) |
| SI (1) | SI2534242T1 (enExample) |
| WO (1) | WO2011098516A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014096033A1 (en) | 2012-12-18 | 2014-06-26 | Immunicum Ab | Co-differentiation of monocytes from allogeneic donors |
| EP3291821B1 (en) * | 2015-05-07 | 2026-02-25 | Baylor College of Medicine | Dendritic cell immunotherapy |
| CN105695403A (zh) * | 2015-12-31 | 2016-06-22 | 深圳市中美康士生物科技有限公司 | 一种杀伤性免疫细胞的培养方法及其应用 |
| CN105462926A (zh) * | 2015-12-31 | 2016-04-06 | 深圳市中美康士生物科技有限公司 | 一种免疫细胞瘤苗的制备方法及其应用 |
| CN107574149B (zh) * | 2016-07-05 | 2022-02-18 | 上海细胞治疗研究院 | 一种树突状细胞的促成熟方法及其用途 |
| CN106085960A (zh) * | 2016-07-28 | 2016-11-09 | 广州赛莱拉干细胞科技股份有限公司 | 一种培养dc细胞的培养基及培养方法 |
| US11976299B2 (en) | 2016-09-23 | 2024-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
| GB201711379D0 (en) * | 2017-07-14 | 2017-08-30 | Univ Cape Town | Maturation of dendritic cells |
| ES2769128T3 (es) * | 2017-09-20 | 2020-06-24 | Immunicum Ab | Células dendríticas alogénicas mejoradas para uso en el tratamiento de cáncer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| AU2003293411B2 (en) * | 2002-12-06 | 2010-10-28 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| EP1840206A1 (en) | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| WO2008110569A1 (en) * | 2007-03-12 | 2008-09-18 | Bioneer A/S | Method for determination of immunomodulatory effect |
| KR101932027B1 (ko) * | 2007-10-08 | 2018-12-24 | 인트렉손 코포레이션 | 가공된 수지상 세포 및 암의 치료를 위한 이의 용도 |
| US8728806B2 (en) * | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
| CN101481677B (zh) * | 2009-01-22 | 2011-12-14 | 复旦大学附属华山医院 | 体外刺激树突状细胞成熟的方法 |
-
2011
- 2011-02-10 JP JP2012552394A patent/JP5855018B2/ja not_active Expired - Fee Related
- 2011-02-10 EP EP11702471.1A patent/EP2534242B1/en active Active
- 2011-02-10 US US13/522,741 patent/US9034317B2/en active Active
- 2011-02-10 HU HUE11702471A patent/HUE028352T2/en unknown
- 2011-02-10 PL PL11702471.1T patent/PL2534242T3/pl unknown
- 2011-02-10 CN CN201180008012.3A patent/CN102782123B/zh not_active Expired - Fee Related
- 2011-02-10 WO PCT/EP2011/051952 patent/WO2011098516A1/en not_active Ceased
- 2011-02-10 KR KR1020127021390A patent/KR101770785B1/ko active Active
- 2011-02-10 BR BR112012019267-1A patent/BR112012019267B1/pt not_active IP Right Cessation
- 2011-02-10 SI SI201130868A patent/SI2534242T1/sl unknown
- 2011-02-10 DK DK11702471.1T patent/DK2534242T3/en active
- 2011-02-10 RU RU2012137173/10A patent/RU2565542C2/ru active
- 2011-02-10 ES ES11702471.1T patent/ES2581277T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519363A5 (enExample) | ||
| Zhang et al. | Neutrophils in cancer development and progression: roles, mechanisms, and implications | |
| RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
| RU2015154737A (ru) | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности | |
| RU2017121191A (ru) | Методика размножения гамма-дельта Т-клеток | |
| JP2006525995A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2015524849A5 (enExample) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| ES2959218T3 (es) | Composición para mejorar los niveles de biomarcadores anti-envejecimiento en un receptor | |
| RU2014111662A (ru) | Лечение кахексии | |
| RU2018123666A (ru) | Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина | |
| RU2012137173A (ru) | Улучшенная композиция для ингибирования пролиферации опухолевых клеток | |
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
| US20200069677A1 (en) | Markers for personalized cancer treatment with lsd1 inhibitors | |
| RU2015105821A (ru) | Способ адъювантного лечения рака | |
| JP2012506394A5 (enExample) | ||
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| CA3101035A1 (en) | Methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene | |
| DE60226517D1 (de) | Dipeptidyl peptidase iv inhibitoren zur senkung der chronische gewichtszunahme | |
| NO20082566L (no) | Kombinasjon av AZ2171 og permetrexed | |
| JP2018522880A5 (enExample) | ||
| JP2013507945A5 (enExample) | ||
| HRP20141230T1 (hr) | Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica |